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Introduction 
Multiple Sclerosis is a disease affecting 2 million people worldwide. It is caused by a complex immune response against the myelin sheaths around the axons in the Central Nervous System.  
Antigen presenting cells recognize myelin peptides as exogenous and present them to T cells using MHC class I and II. Those T cells activate the immune response, where antibodies, complement, 
macrophages recruitment and inflammation cause the destruction of neurons. 
Typically, Multiple Sclerosis is treated with oral or intravenous Interferon Beta, which has several immunomodulatory properties. Because of the lack of an efficient treatment, an ex vivo gene therapy 
approach with Interferon Beta-producing Mesenchymal Stem Cells has been tested in mice. This treatment has been shown to reduce myelin destruction, inflammation and lymphocytic infiltration. 
The aim of this project is to study the effect of this treatment in antigen presenting to further understand the pathways involved in its immunomodulatory effect. 
Hypothesis 
Scientific literature search on PubMed database: Recent papers and reviews were selected according to their 
quality and data of publication. Two main topics were used for the search: 
ØMultiple Sclerosis: its clinics, pathology, actual therapies and new experimental approaches using gene therapy. 
ØInterferon Beta: immunomodulatory effects, role in MHC class II antigen presenting, uses in gene therapy. 
Interview to a scientist working in the field of gene therapy for the CNS: Miguel Chillón (CBATEG, UAB) 















In vitro studies have demonstrated that Interferon 
Beta downregulates class II MHC antigen 
presenting by blocking the CIITA-driven 
transcription of class II MHC.  
Because of this, treatment with Interferon Beta-
secreting Mesenchymal Stem Cells should reduce 
antigen presenting by this same pathway, as one of 
its many immunomodulatory eftects. 
ØSurvival and Clinical Score study. 
ØClass II MHC expression study by Immunohistochemistry: Expected reduction of 
expression. 
ØMHC class II pathway genes activity study by RT-PCR: CIITA mRNA levels are expected to 
be mantained, and MHC class II mRNA levels reduced.  
Experimental Design 
ØProduction of a lentiviral vector encoding the gene for Interferon Beta 
under control of the ubiquous Cytomegalovirus (CMV) promoter. 
ØHuman Bone Marrow-derived Mesenchymal Stem Cell culture and 
transfection with the lentiviral vectors. 
ØTreatment of EAE induced mice with the Interferon Beta-secreting 
Mesenchymal Stem Cells. 
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ØSplenocytes 
reactivity to myelin 
peptides assay: 
Splenocytes are isolated, 
cultured in a medium with 
myelin peptides and their 
reactivity is studied by 
antibody staining against 
T cell marker CD3 and 
activity marker CD25.  
Immunomodulatory effect 
is not expected 
systemically. 
 
